Claudia Del Grande

Claudia Del Grande

Auto-generated profile, based on publicly available information

Claudia Del Grande

Department of Clinical and Experimental Medicine, Section of Psychiatry, University of Pisa, Via Roma 67, 56127 Pisa, Italy

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 January 2017 in Pathogens
Verified
Journal Article
Open access
PDF file
CGClaudia Del Grande
Claudia Del Grande
LGLuca Galli
Luca Galli
ESElisa Schiavi
Elisa Schiavi
Liliana Dell'OssoLiliana Dell'Osso
Liliana Dell'Osso
Fabrizio BruschiFabrizio Bruschi
Fabrizio Bruschi
Toxoplasma gondii, a ubiquitous intracellular parasite, has a strong tropism for the brain tissue, where it forms intracellular cysts within the neurons and glial cells, establishing a chronic infection. Although latent toxoplasmosis is generally assumed to be asymptomatic in immunocompetent individuals, it is now clear that it can induce behavioral manipulations in mice and infected humans. Moreover, a strong relation has emerged in recent years between toxoplasmosis and psychiatric disorders. The link between T. gondii and schizophrenia has been the most widely documented; however, a significant association with bipolar disorder (BD) and suicidal/aggressive behaviors has also been detected. T. gondii may play a role in the etiopathogenesis of psychiatric disorders affecting neurotransmitters, especially dopamine, that are implicated in the emergence of psychosis and behavioral Toxoplasma-induced abnormalities, and inducing brain inflammation by the direct stimulation of inflammatory cytokines in the central nervous system. Besides this, there is increasing evidence for a prominent role of immune dysregulation in psychosis and BD. The aim of this review is to describe recent evidence suggesting a link between Toxoplasma gondii and BD, focusing on the interaction between immune responses and this infectious agent in the etiopathogenesis of psychiatric symptoms.

1 November 2013 in International Clinical Psychopharmacology
Verified
Journal Article
Closed access
MMMatteo Muti
Matteo Muti
CGClaudia Del Grande
Claudia Del Grande
LMLaura Musetti
Laura Musetti
Donatella MarazzitiDonatella Marazziti
Donatella Marazziti
IPIrene Pergentini
Irene Pergentini
Liliana Dell'OssoLiliana Dell'Osso
Liliana Dell'Osso
The present study aimed to identify the prescribing patterns of lithium or of lithium+valproate in 75 bipolar I outpatients in a manic or a mixed phase within a naturalistic setting. The differences between the two treatments and the correlation between serum lithium levels and response were also examined. The results showed that patients with lithium levels of 0.60 mEq/l or more had higher remission rates and greater symptom reduction than the other patients. Patients on lithium and valproate showed greater improvement in mixed, anxiety, and psychotic symptoms than those on lithium only, as assessed by the Clinical Global Impression-Bipolar version scale scores. Finally, our findings suggest that a range of lithium levels between 0.40 and 0.60 mEq/l, albeit below the therapeutic range, seems sufficient to maintain a good effect when lithium is coadministered with valproate

1 January 2012
Verified
Journal Article
Closed access
PDF file
CGClaudia Del Grande
Claudia Del Grande
MMMatteo Muti
Matteo Muti
LMLaura Musetti
Laura Musetti
IPIrene Pergentini
Irene Pergentini
MCMartina Corsi
Martina Corsi
Liliana Dell'OssoLiliana Dell'Osso
Liliana Dell'Osso